CombiGene’s rights issue subscribed with over 80 percent
CombiGene AB (“CombiGene” or the “Company”) has completed the rights issue of shares and warrants, so called units, resolved by the Board of Directors on 18 February 2020. The subscription period ran from and including 20 March 2020 to and including 3 April 2020. The total value of the subscriptions in the rights issue amounts to MSEK 26.28 before issue costs.
The final result shows that units amounting to MSEK 13.44 were subscribed for with preferential rights, corresponding to 41.3 percent of the rights issue. Units amounting to MSEK 12.84 were subscribed for without preferential rights. Thus, units worth MSEK 26,28 were subscribed for in total, which equals a subscription rate of 80.81 percent.
The rights issue will provide the Company with MSEK 26,28 before issue costs, which will amount to MSEK 1.5. Guarantees will not be exercised.
The allocation of subscribed units will be made in accordance with the principles stipulated in the prospectus dated 19 March 2020. A notification on allocation of units subscribed for without unit rights will be made through a contract note that will be sent to each such subscriber on 9 April 2020. Payment for units subscribed for without the exercise of unit rights shall be made in accordance with the instruction on the contract note. A notification will only be sent to those who have subscribed for units without the exercise of unit rights and that have been allocated units.
Through the rights issue the share capital of CombiGene will increase with SEK 5,256,836 by issuing 52,568,360 shares. After the rights issue the share capital will amount to SEK 11 762 200,70 and the number of shares will amount to 117,622,007.
Paid subscribed units will be traded on Nasdaq First North Growth Market up until the Swedish Companies Registration Office has registered the rights issue and will thereafter automatically be replaced with shares and warrants of series TO3 and TO4.
Comments by the CEO, Jan Nilsson
”CombiGene’s rights issue was carried out under a period when the covid-19 pandemic affected all parts of our society. I consider it to be a very good outcome that the rights issue had a subscription rate of more than 80 percent under these circumstances and this means that we can continue to carry out our projects. We have recently published several important steps concerning our ambition towards entering the clinical phase within 2 years and we look forward towards publishing several important steps of progress in the nearby future”.
For further information, please contact
Jan Nilsson, CEO
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.